Loading…
Develops targeted protein degradation drugs that use the body's own disposal system to eliminate disease-causing proteins.
Develops targeted protein degradation drugs that use the body's own disposal system to eliminate disease-causing proteins.
Revenue comes from collaboration payments by partners such as Gilead and Sanofi, not from product sales, in the form of upfront fees, research funding and milestone payments, so income depends on partner programs advancing. Its own BTK-degrader drugs are in clinical trials and funded by investors and those partner payments.
Moat: narrow (IP / patents, process know-how). Proprietary protein-degradation discovery platform with major pharma partnerships including Gilead and Sanofi.
Headquarters: San Francisco, California, US · Founded: 2009 · Employees: 317
Size Nurix Therapeutics (NRIX) is a United States Health Care company (Biotechnology) with a market value of $1.67B, the 1915th largest of 3,117 United States companies the cockpit tracks. Shares closed at $15.30 on 6 Nov 2026.
Performance Over six months the shares fell 7.4%, against -8.7% for the median peer and -1.1% for the United States market (cap-weighted) — 9th highest of 18 in its peer set.
Growth Revenue grew 738.8% over the last twelve months (peer median +21.1%); the operating margin is 41.3% (peer median -37.5%).
Valuation It trades at 1.0× enterprise value to sales against a peer median of 17.1× (cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -19% a year for seven years (Req g). Recent delivered growth is +36%, so the hurdle is -55 pp: the price already allows for a slowdown.
Short interest Short interest is 18.9% of the free float (15 Oct 2026).
Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $702M | $84.0M | $54.5M | $77.0M | $38.6M |
| Revenue growth | — | +54% | -29% | +99% | — |
| Gross profit | $686M | $65.1M | $38.1M | $63.3M | $27.8M |
| EBITDA | $306M | -$267M | -$197M | -$141M | -$173M |
| Net income | $295M | -$264M | -$194M | -$144M | -$180M |
| Free cash flow | $370M | -$263M | -$182M | -$89.8M | -$172M |
| Capital expenditure | $9.50M | $14.0M | $9.27M | $8.40M | $12.2M |
| Total debt | $65.3M | $55.7M | $28.3M | $30.6M | $12.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Nurix Therapeutics NRIX | $1.67B | -7% | +739% | 41% | 1.0× | -19.0% |
| Arvinas ARVN | $420M | -37% | -12% | -10% | n/a | n/a |
| C4 Therapeutics CCCC | $381M | +5% | +2% | -288% | 5.3× | n/a |
| Kymera Therapeutics KYMR | $11.2B | +53% | +134% | -396% | 101.2× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NRIX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -31.1% | -8.8% | 2nd lowest of 20 |
| 6-month return | -7.4% | -8.7% | 9th highest of 18 |
| Distance from 52-week high | -45.8% | -38.6% | 8th lowest of 20 |
| Revenue growth (TTM) | +738.8% | +21.1% | 2nd highest of 19 |
| Operating margin | 41.3% | -37.5% | highest of 19 |
| EV / Sales | 1.0× | 17.1× | cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -19.0% | n/a | — |
| Growth delivered (Del g) | +36.4% | n/a | — |
| Hurdle (Req g minus delivered) | -55.3 pp | n/a | — |
| EV / EBITDA | 2.3× | n/a | — |
| Net debt / EBITDA | -3.2× | 1.0× | 2nd least indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nurix Therapeutics NRIX | United States | $1.67B | -7% | +739% | 41% | 1.0× | -19.0% | +36.4% |
| Generate Biomedicines GENB | United States | $1.68B | -4% | +56% | -737% | 40.2× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | 369.5× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.68B | -40% | n/a | n/a | n/a | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | 231.2× | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.71B | -5% | +36% | -4% | 8.7× | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.71B | -9% | +12% | 8% | 14.8× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.72B | +45% | +16% | -5% | 6.2× | 45.1% | -2.5% |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 3.3× | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.74B | -19% | -86% | -913% | 50.3× | n/a | n/a |
| Absci ABSI | United States | $1.75B | +72% | -62% | -8,411% | 991.7× | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 19.4× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.76B | n/a | -55% | -593% | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.76B | -23% | +71% | 0% | 4.5× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |
| Novavax NVAX | United States | $1.78B | +7% | -62% | -29% | 3.3× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 1.8× | -4.1% | +33.5% |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | n/a | n/a | n/a |